Drug intelligence / Profile preview

Virulence Modifying Proteins

Development stage
Preclinical
Lead developer
Yale University
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular, Subcutaneous
01

Overview

Virulence Modifying Proteins (VMPs) are a family of conserved, secreted exotoxins encoded by the PF07598 gene family in pathogenic *Leptospira* species. These proteins feature N-terminal ricin B-like lectin domains and a C-terminal toxin domain with DNase activity, which mediates host cell cytotoxicity, endothelial dysfunction, and tissue damage. Recombinant VMPs are under development as vaccine antigens to provide serovar-independent, pan-leptospirosis protection. Immunization with these recombinant proteins, formulated with a glucopyranoside lipid A/squalene oil-in-water adjuvant, has been shown to protect animal models (such as mice and hamsters) from lethal challenge and significantly reduce bacterial loads in the liver and kidneys. Additionally, VMPs (such as the LA0591 and LA3490 variants) are being investigated as diagnostic biomarkers for the early detection of leptospirosis.

Other names
VM proteinsVMP vaccinerecombinant VM proteinsrecombinant VMP vaccinerecombinant virulence-modifying proteins
02

Targets

TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on Virulence Modifying Proteins.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Virulence Modifying Proteins.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call